|
| 34998634 | EJSO educational Special issue from the TARPSWG - Standard medical treatment and new options in retroperitoneal sarcoma. | Eur J Surg Oncol | 2023 |
| 37598656 | Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study. | Eur J Cancer | 2023 |
| 37586768 | Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. | J Immunother Cancer | 2023 |
| 37829338 | Case report: The activity of multi-kinase VEGF inhibitor, Pazopanib, in metastatic undifferentiated round cell sarcomas harboring <i>EWSR1::CREM</i> fusion: clinicopathological series of two cases and literature review. | Front Oncol | 2023 |
| 37828359 | Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors. | Nat Med | 2023 |
| 37768856 | Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1) Is a Novel Therapeutic Target in Liposarcoma: A Tissue Microarray Study. | Clin Orthop Relat Res | 2023 |
| 37017908 | Osteogenic Sarcoma of the Head and Neck: Is Chemotherapy Needed? | Curr Treat Options Oncol | 2023 |
| 37143339 | Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry. | Cancer Invest | 2023 |
| 37105265 | Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib. | Ann Oncol | 2023 |
| 37271655 | CivaSheet® use for soft tissue sarcoma: A single institution experience. | Brachytherapy | 2023 |
| 36853730 | Optimized lentiviral vector transduction of adherent cells and analysis in sulforhodamine B proliferation and chromatin immunoprecipitation assays. | STAR Protoc | 2023 |
| 36525371 | Expanding access to early phase trials: the CATCH-UP.2020 experience. | JNCI Cancer Spectr | 2023 |
| 35108034 | Treatment of Disseminated Intravenous Leiomyomatosis With ALK Targeting Crizotinib: A Successful Case Report. | JCO Precis Oncol | 2022 |
| 35672677 | Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib. | BMC Cancer | 2022 |
| 35367753 | Inhibition of CDK7-dependent transcriptional addiction is a potential therapeutic target in synovial sarcoma. | Biomed Pharmacother | 2022 |
| 36031697 | Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. | Cancer Treat Rev | 2022 |
| 35947817 | Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. | J Clin Oncol | 2022 |
| 36077869 | Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study. | Cancers (Basel) | 2022 |
| 35180772 | Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study. | Clin Cancer Res | 2022 |
| 35275323 | What Clinical Trials Are Needed for Treatment of Leiomyosarcoma? | Curr Treat Options Oncol | 2022 |
| 35198082 | IDH1 Mutation Induces HIF-1<i>α</i> and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells. | Dis Markers | 2022 |
| 33301227 | Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. | Oncologist | 2021 |
| 33672607 | Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). | Cancers (Basel) | 2021 |
| 33802383 | Pathologic Response Rates after Neoadjuvant Therapy for Sarcoma: A Single Institution Study. | Cancers (Basel) | 2021 |
| 34817950 | The efficacies and biomarker investigations of antiprogrammed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma. | Cancer Biol Med | 2021 |
| 34638300 | Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis. | Cancers (Basel) | 2021 |
| 34489967 | Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors. | Front Immunol | 2021 |
| 34453383 | A nonrandom association of breast implants and the formation of desmoid tumors. | Breast J | 2021 |
| 34391056 | Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. | Eur J Cancer | 2021 |
| 34415314 | Variation in Management of Extremity Soft-Tissue Sarcoma in Younger vs Older Adults. | JAMA Netw Open | 2021 |
| 33995633 | Severity of COVID-19 in Cancer patients versus patients without Cancer: A Propensity Score Matching Analysis. | J Cancer | 2021 |
| 34326023 | Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline. | Pract Radiat Oncol | 2021 |
| 34298737 | Immunotherapy Strategies for Gastrointestinal Stromal Tumor. | Cancers (Basel) | 2021 |
| 34213370 | MRI Volumetrics and Image Texture Analysis in Assessing Systemic Treatment Response in Extra-Abdominal Desmoid Fibromatosis. | Radiol Imaging Cancer | 2021 |
| 33983905 | ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control. | J Clin Invest | 2021 |
| 34343033 | Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. | J Clin Oncol | 2021 |
| 34236401 | Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial. | JAMA Oncol | 2021 |
| 34359716 | Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable. | Cancers (Basel) | 2021 |
| 33453089 | Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. | Oncologist | 2021 |
| 32191549 | Progress in determining response to treatment in gastrointestinal stromal tumor. | Expert Rev Anticancer Ther | 2020 |
| 36751526 | Identification of Genetic Alterations by Circulating Tumor DNA in Leiomyosarcoma: A Molecular Analysis of 73 Patients. | J Immunother Precis Oncol | 2020 |
| 35050730 | Utility of Circulating Tumor DNA in the Management of Patients With GI Stromal Tumor: Analysis of 243 Patients. | JCO Precis Oncol | 2020 |
| 31935911 | Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth. | Cancers (Basel) | 2020 |
| 31904710 | Low Frequency of Mutation Testing in the United States: An Analysis of 3866 GIST Patients. | Am J Clin Oncol | 2020 |
| 32804590 | Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. | J Clin Oncol | 2020 |
| 32615108 | Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. | Lancet Oncol | 2020 |
| 32529020 | CIC-rearranged round cell (Ewing-like) sarcoma of the uterus: Review of the literature. | Gynecol Oncol Rep | 2020 |
| 32208957 | Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. | J Clin Oncol | 2020 |
| 30652922 | How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers. | Curr Med Res Opin | 2019 |
| 32053767 | Precision medicine in gastrointestinal stromal tumors. | Discov Med | 2019 |